Frequently Asked Questions

Frequently Asked Questions

Why LLS?

The Leukemia & Lymphoma Society (LLS) is the global leader in the fight to end blood cancer, dedicated to funding research, finding cures and ensuring access to treatments for blood cancer patients. The mission of The Leukemia & Lymphoma Society (LLS) is: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families.

Since 1949, LLS has been at the forefront of blood cancer advances such as chemotherapies and stem cell transplantation, leading the way to the targeted therapies and immunotherapies that are saving thousands of lives today. Despite advances in treatment, not all patients have access to the latest therapies. At LLS, we are determined to change this. We believe every patient deserves to receive the best care and support possible.

What is Myeloma link?

Myeloma is the most common blood cancer among Black Americans. Further, the incidence of myeloma is twice as high among Black Americans as white Americans, and Black patients are less likely to have access to timely, optimal treatment and care.. As champions for access to care, LLS is dedicated to changing this. Carried out by LLS staff and volunteers in 13 Black communities across the country, Myeloma Link is an education and outreach program that directly connects Black patients and caregivers to trusted, free myeloma information and support and enhances access to care and the latest treatments.

To learn more about Myeloma Link and how you can participate, please call 1(844) 955-LINK or email MyelomaLink@lls.org. To read more about myeloma, please click here.

What is special about this program?

The Leukemia & Lymphoma Society (LLS) is partnering with a wide range of trusted partners within Black communities, including churches, senior centers, and community health centers, in order to:

  • Raise awareness among Black Americans about the disparities in myeloma incidence and treatment, signs and symptoms of the disease, and the wide array of trusted, free resources that LLS offers to patients and families dealing with blood cancer;
  • Provide information and resources that will equip Black patients with myeloma with the knowledge and tools needed to seek novel, state-of-the-art treatments, including clinical trials, in a timely manner.

Where is Myeloma Link offered?

Currently, this free educational and outreach program is offered virtually in Atlanta, Baltimore, Birmingham, Cleveland, Dallas, Detroit, Houston, New York City/The Bronx, Oakland, Philadelphia, Raleigh-Durham, St. Louis and Washington D.C., providing free education, information, support, and referral resources. Patients, caregivers, and healthcare professionals can access the program through online webinars from the comfort of home.

How can I find out more about Myeloma Link, including how to participate?

If Myeloma Link is in your community, learn how you can participate by calling 1-844-955-LINK or emailing MyelomaLink@LLS.org today. LLS welcomes patients, caregivers, and healthcare professionals to take part in this free educational program.

Black Americans are affected by all types of blood cancers, so why the focus on myeloma?

Myeloma is the most common blood cancer among Black Americans. In addition, the incidence of myeloma is twice as high among Black Americans as white Americans. Recent studies show that Black Americans are significantly less likely to receive the newest treatments and combination therapies, and more likely to experience treatment delays, including transplant delays.

Myeloma Link is connecting Black communities to trusted, free information, expert Care, and support.

What other programs does LLS offer

LLS offers a vast array of free education and support, including professional, one-on-one support, peer-to-peer support, financial assistance, a podcast, online chats, webcasts, videos, and so much more. LLS looks to reach all blood cancer patients early in their diagnosis to help connect them with vital information, resources and support. For more information, click here